OBJECTIVE: A novel lipoprotein lipase (LPL)-like gene, endothelial cell-derived lipase (EDL), was recently cloned from vascular endothelial cells. The presence of LPL in the vascular wall has been implicated in the progression of atherosclerosis through the bridging function between lipoprotein particles and matrix proteoglycans to enhance lipoprotein uptake into the vascular wall. The aim of this study was to investigate the local expression of EDL in human coronary arteries. METHODS AND RESULTS: Human coronary arterial specimens from 10 autopsied cases were examined by immunohistochemistry with polyclonal antibodies against specific synthetic EDL peptides. Immunohistochemical analysis revealed that EDL was expressed in endothelial cells and medial smooth muscle cells in non-atherosclerotic coronary arteries. In addition, EDL was expressed in infiltrating cells within atheromatous plaques as well as endothelial and smooth muscle cells. Double labeling immunofluorescence confirmed EDL positive-cells were endothelial cells, smooth muscle cells and macrophages. EDL immunoreactivity was also detected in neovasculature within atheromatous plaques in atherosclerotic coronary arteries. CONCLUSIONS: These results suggest that EDL may have unique functional roles in the pathogenesis of coronary artery diseases such as atherosclerosis as well as in lipid metabolism in the vessel wall.
OBJECTIVE: A novel lipoprotein lipase (LPL)-like gene, endothelial cell-derived lipase (EDL), was recently cloned from vascular endothelial cells. The presence of LPL in the vascular wall has been implicated in the progression of atherosclerosis through the bridging function between lipoprotein particles and matrix proteoglycans to enhance lipoprotein uptake into the vascular wall. The aim of this study was to investigate the local expression of EDL in human coronary arteries. METHODS AND RESULTS:Human coronary arterial specimens from 10 autopsied cases were examined by immunohistochemistry with polyclonal antibodies against specific synthetic EDL peptides. Immunohistochemical analysis revealed that EDL was expressed in endothelial cells and medial smooth muscle cells in non-atherosclerotic coronary arteries. In addition, EDL was expressed in infiltrating cells within atheromatous plaques as well as endothelial and smooth muscle cells. Double labeling immunofluorescence confirmed EDL positive-cells were endothelial cells, smooth muscle cells and macrophages. EDL immunoreactivity was also detected in neovasculature within atheromatous plaques in atherosclerotic coronary arteries. CONCLUSIONS: These results suggest that EDL may have unique functional roles in the pathogenesis of coronary artery diseases such as atherosclerosis as well as in lipid metabolism in the vessel wall.
Authors: Andrew L Darrow; Matthew W Olson; Hong Xin; Sharon L Burke; Charles Smith; Celine Schalk-Hihi; Robyn Williams; Shariff S Bayoumy; Ingrid C Deckman; Matthew J Todd; Bruce P Damiano; Margery A Connelly Journal: J Lipid Res Date: 2011-02 Impact factor: 5.922
Authors: Jon J Hangeland; Lynn M Abell; Leonard P Adam; Ji Jiang; Todd J Friends; Lauren E Haque; James Neels; Joelle M Onorato; Alice Ye A Chen; David S Taylor; Xiaohong Yin; Thomas W Harrity; Michael D Basso; Richard Yang; Paul G Sleph; David A Gordon; Christine S Huang; Ruth R Wexler; Heather J Finlay; R Michael Lawrence Journal: ACS Med Chem Lett Date: 2018-06-15 Impact factor: 4.345
Authors: Margery A Connelly; Michael R D'Andrea; Jenson Qi; Keli C Dzordzorme; Bruce P Damiano Journal: J Histochem Cytochem Date: 2012-06-26 Impact factor: 2.479
Authors: Un Ju Jung; Claudia Torrejon; Chuchun L Chang; Hiroko Hamai; Tilla S Worgall; Richard J Deckelbaum Journal: Arterioscler Thromb Vasc Biol Date: 2012-10-04 Impact factor: 8.311